No connection

Search Results

NAMSW

BEARISH
$23.4 Live
NewAmsterdam Pharma Company N.V. · NASDAQ
$7.16 52W Range $29.99
Overview AI Snowflake Price Valuation Profitability Growth Health Statements

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 15, 2026
Market cap
N/A
P/E
N/A
ROE
-28.3%
Profit margin
N/A
Debt/Equity
0.0
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
NAMSW exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe operational weakness. The company has suffered a catastrophic revenue collapse of -99.80% YoY, coupled with an extreme negative operating margin of -206,187.50%. While the balance sheet remains liquid with a Current Ratio of 7.88 and zero debt, the lack of income generation and negative ROE (-28.29%) suggest a failing business model. Historical price gains appear disconnected from current fundamental decay.

Key Strengths

Zero debt (Debt/Equity: 0.00)
High short-term liquidity (Current Ratio: 7.88)
Strong historical 5-year price appreciation (+2322.4%)
High Quick Ratio (7.69) indicating cash/near-cash availability
100% Gross Margin (likely due to negligible COGS relative to minimal revenue)

Key Risks

Catastrophic revenue decline (-99.80% YoY)
Extreme operating losses (-206,187.50% Operating Margin)
Critical operational health (Piotroski F-Score: 1/9)
Negative returns on equity and assets (ROE: -28.29%, ROA: -17.27%)
Complete lack of analyst coverage and institutional guidance

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
23
Weak
Value
20
Future
5
Past
80
Health
10
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Revenue collapse, Piotroski F-Score 1/9, Extreme operating losses
Confidence
90%
Value
20/100

Graham Number is unavailable; valuation is purely speculative.

Positives
  • No debt
Watchpoints
  • P/B of 3.92 is high for a company with no revenue
  • No P/E or PEG available due to losses
Future
5/100

Growth metrics indicate a near-total cessation of business operations.

Positives
No standout positives identified.
Watchpoints
  • Revenue growth -99.80% YoY
  • Q/Q Revenue growth -99.75%
Past
80/100

Historical price performance is strong but fundamentally unsupported by current data.

Positives
  • Massive 5Y and 3Y price gains
Watchpoints
  • Recent 6M trend is negative (-10.7%)
Health
10/100

Strong liquidity is the only factor preventing immediate insolvency, but operational health is critical.

Positives
  • High Current Ratio
  • Zero Debt
Watchpoints
  • Piotroski F-Score 1/9
  • Negative ROE/ROA
Dividend
0/100

Dividend Strength 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity to pay dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$23.4

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for NAMSW and closest competitors.

Updated 2026-04-14
NAM
NewAmsterdam Pharma Company N.V.
Primary
5Y
+2322.4%
3Y
+836.0%
1Y
+190.7%
6M
-10.7%
1M
+26.5%
1W
-1.3%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
3.92
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
N/A
Market Cap
N/A

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -206188.0%
Gross Margin 100.0%
ROE -28.29%
ROA -17.27%

Growth

Revenue and earnings growth rates

Revenue Growth -99.8%
Earnings Growth N/A
Q/Q Revenue Growth -99.75%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.0
Low debt
Current Ratio
7.88
Strong
Quick Ratio
7.69
Excellent
Cash/Share
$5.53

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Op. Margin
-206187.5%
Net Margin
-234134.4%
Total Assets
$0.8B
Liabilities
$0.1B
Equity
$0.7B
Debt/Equity
0.13x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Past News Coverage

Recent headlines mentioning NAMSW from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile